Day: October 6, 2021

ASTONISHING JOURNEYS TO CELEBRATE TIME WITH FRIENDS AND FAMILY

Fully bespoke multi-generational adventures to reunite loved ones

London, October 6, 2021: Reunion noun. /ˌriːˈjuːniən/ — The act of people coming together after they have been apart for some time.

VistaJet, the first and only global business aviation company, today announced the launch of The Surprise Reunion, its latest creation in the Adventures in the Sky program for families. Designed in collaboration with world-renowned event planners Sharky & George, the thrilling adventures bring friends and families together from every corner of the globe. Whether on a little known sandy island in the Pacific Ocean or a stunning mountain with untouched snow as far as the eye can see, gatherings will be completely unique and original.

Prior to each journey, exciting and mysterious packages, including trip itineraries and challenge instructions, are delivered at each guest’s door. Perhaps an ancient map parchment, a set of engraved coins, or a cryptic message, each will be different from the next — and in some cases, delivered by unexpected characters. From there, VistaJet will ensure seamless travel by private jet from anywhere in the world, to the final destination.

With unparalleled experience flying into and out of the hardest to reach destinations and onboard service unlike any other, The Surprise Reunion flights are remarkable. As friends and family may be flying simultaneously on separate VistaJet aircraft, all in-flight activities and challenges will share a common theme to create an atmosphere of togetherness leading up to the reunion.

Matteo Atti, EVP of Marketing and Innovation at VistaJet said: “This past year has shown us that spending time with family and friends is what really matters. We assessed how to better serve our Members and imagined a reunion with loved ones of all ages, commencing at 45,000ft in the sky. In collaboration with our longstanding partner Sharky & George, we did just that by creating The Surprise Reunion.

After more than a year of missed milestones and holiday gatherings, our hope is that this will give families and friends something exciting to look forward to, encouraging them to spend time together, exploring new places, creating new traditions, and celebrating every moment big and small.”

VistaJet’s Surprise Reunion can be completely tailored to meet passenger preferences and create the most imaginative experience. Inspiration itineraries include:

• The Ultimate Quest: Imagine the world’s most elaborate treasure hunt that starts at home and culminates in all the family’s favorite people congregating on a private island surrounded by turquoise sea. Hidden maps and cryptic clues will be found along the way, interacting with characters who are not what they initially seem. Expect boat chases, drone delivery of intel, femmes fatales, buried chests, high-tech spy equipment, and a nail-biting narrative to inspire and excite all ages.
• Adventure Race Across the Globe: Perfect for family and friends with a competitive streak. Teams are allocated one month before the VistaJet flights and are evenly split between ages, ability and geography. As soon as race packs are delivered, players will have time to collaborate on tactics and game plans. Upon arrival at the top of a mountain, in a beautiful chalet surrounded by pristine powder, the group receives a set of photos, video and physical challenges to kick off a week-long adventure, paramotoring over the peaks, tracking chamois, marmot or elk with a local biologist, and dog sledding to dinner.
• Immersive Historical Experience: Travel back in time to Ancient Greece, where everyone will convene aboard a spectacular superyacht for two weeks in the Peloponnese to embark on a modern take on the 12 Labors of Hercules. Clues and challenges will be woven into the most unusual activities imaginable, from cave diving to capture Hydra from the bed of the sea, to recovering Golden Apples from the top of Mount Olympus in a climb to Greece’s highest peak.

For more information on VistaJet and its Adventures in the Sky offerings, please visit vistajet.com/children

– Ends –

Information
VistaJet | press@vistajet.com

About VistaJet 
VistaJet is the first and only global business aviation company. On its fleet of over 70 silver and red business jets, VistaJet has flown corporations, governments and private clients to 187 countries, covering 96% of the world. Founded in 2004, the company pioneered an innovative business model where customers have access to an entire fleet whilst paying only for the hours they fly, free of the responsibilities and asset risks linked to aircraft ownership. VistaJet’s signature Program membership offers customers a bespoke subscription of flight hours on its fleet of mid and long-range jets, to fly them anytime, anywhere.
VistaJet is part of Vista Global Holding — the world’s first private aviation ecosystem, integrating a unique portfolio of companies offering asset-light solutions to cover all key aspects of business aviation.
More VistaJet information and news at vistajet.com

VistaJet Limited is a European air carrier that operates 9H registered aircraft under its Maltese Air Operator Certificate No. MT-17 and is incorporated in Malta under Company Number C 55231. VistaJet US Inc. is an Air Charter Broker that does not operate aircraft. VistaJet and its subsidiaries are not U.S. direct carriers. VistaJet-owned and U.S. registered aircraft are operated by properly licensed U.S. air carriers, including XOJET Aviation LLC.

Attachments

• The Surprise Reunion
• Onboard fun

Covicept Therapeutics initiates a Phase 2 clinical study with PJS-539, an oral small molecule for the treatment of patients with COVID-19 (SARS-CoV-2)

• Covicept has initiated a Phase 2 multi-center, randomized, double-blind, placebo-controlled 150 patient clinical trial in Brazil
• The study will evaluate safety and efficacy of PJS-539 in reducing viral load in patients with COVID-19
• PJS-539 is a potent, once daily, oral pill that inhibits attachment, infection and replication of SARS-CoV-2 and other RNA viruses
• Covicept is a California-based biotech company funded and operationally supported by Forbion, a leading European life sciences venture capital firm

San Diego, USA, October 6^th, 2021 – Covicept Therapeutics, an antiviral drug development company, announced today that a double-blind, placebo-controlled Phase 2 trial of PSJ-539 has been initiated and has begun enrolling patients with mild-to-moderate COVID-19. PSJ-539 has the potential to become a best-in-class small molecule for the treatment of COVID-19 patients and also has potential as a broad-spectrum antiviral drug targeting RNA viruses.

This multi-center, randomized, double-blind, placebo-controlled Phase 2 clinical trial is designed to evaluate safety and efficacy of PJS-539 in patients recently diagnosed with COVID-19. The trial in up to 150 patients is being conducted in Brazil, led by Bruno M Tomazini, MD of the Hospital do Coração São Paulo. PSJ-539 is administered once a day over ten days and the primary endpoint of the study will be the effect of two different doses of PSJ-539 on viral load compared to placebo. Secondary endpoints include the frequency of hospitalization and need for mechanical ventilation. Results are anticipated by the end of the year (1). The unique mechanism of action of PSJ-539 may prevent or minimize the development of resistance to vaccines and anti-viral medications.

Covicept has discovered several new host-dependent mechanisms by which PSJ-539 inhibits viral infections underscoring its potential as a broad-spectrum antiviral drug targeting RNA viruses (2). In addition, PSJ-539 has strong anti-inflammatory and anti-fibrotic effects in preclinical models of SARS-CoV-2-induced pneumonia. PSJ-539 has previously been tested in human clinical trials, however its anti-viral potential is novel and Covicept holds an exclusive world-wide license to the new patents.

Large scale GMP manufacturing of PSJ-539 has been established.

Professor Tsimikas, Co-Founder, Chairman and Chief Executive Officer of Covicept, commented: “It is a significant milestone for this program to move into clinical development in less than a year since Covicept was founded. Our team, together with Forbion’s operational and financial support, provides the necessary synergy to bring this medicine to patients infected with SARS-CoV-2 as quickly as possible.”

Sander van Deventer, Covicept Board member and Operating Partner at Forbion, added: “Covicept is a great example of how academic researchers, entrepreneurs, and investors can join forces and in a very agile way bring new therapeutic options to patients. PSJ-539 has potential as a prophylactic and to treat early, moderate and severe disease to reduce viral load, to minimize transmission and infection, as well as to reduce the long-term effects. We are very excited by the progress the team has made in the past nine months and continue to support the company on its way to develop potential blockbuster anti-viral drugs.”

RNA viruses such as SARS-CoV-1 (“COVID”), SARS-CoV-2 (“SARS”), MERS-CoV (“MERS”), Dengue, Chikungunya, Zika and Ebola, are considered to be the most likely causes of devastating global pandemics. Vaccination strategies can prevent the spread of these viruses and protect individuals, but they require a significant lead time before implementation and demonstration of efficacy. Hence, a small molecule that can be stockpiled and used to inhibit viral replication would be an integral component of the response to pandemics caused by RNA viruses.

Details of the Covicept PSJ-539 program and results to date will be presented later today by Dr van Deventer at the Sachs 8^th Annual Healthtech Investment Forum in Basel, Switzerland in the Spotlight Showcase at 12.20pm local time.

References

1. Clinicaltrials.gov: https://www.clinicaltrials.gov/ct2/show/NCT05008393?term=covicept&draw=2&rank=1
2. Cell paper: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489987/

About Covicept Therapeutics, Inc.

Covicept Therapeutics, Inc. was founded in 2020 in San Diego, California USA, based on discoveries by Professor Sam Tsimikas, Professor Philip Gordts and Professor Jeffrey Eskowith. It is focused on the development of drugs to treat diseases caused by a variety of RNA viruses, including SARS-CoV-2. It is backed by $2.3 million in seed funding and operational support from leading European VC firm Forbion.

Covicept is developing PSJ-539, a small molecule that inhibits attachment, infection and replication of SARS-CoV-2 and other RNA viruses. PSJ-539 has shown good tolerability and high potency with excellent and high biodistribution to tissues, including the lungs, in humans allowing for relatively low daily doses. PSJ-539 also inhibits fibrosis, a property that may be valuable for patients infected with SARS-CoV-2, both short term and long-term. The unique mechanism of action of PSJ-539 may prevent or minimize the development of resistance to vaccines and anti-viral medications.

About Forbion

Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany and Singapore. Forbion invests in life sciences companies that are active in the
(bio-) pharmaceutical space. Forbion manages well over EUR 1.7 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. Forbion’s current team consists of 20 life sciences investment professionals that have built an impressive performance track record since the late nineties with successful investments in over 70 companies. The firm is a signatory to the United Nations Principles for Responsible Investment. Besides financial objectives, Forbion selects investments that will positively affect the health and well-being of patients. Its investors include the EIF, through its European Recovery Programme (ERP), LfA, Dutch Venture Initiative (DVI), AMUF and EFSI facilities and KfW Capital through the Programme, “ERP – Venture Capital Fonds investments”. Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany. For more information, please visit: www.forbion.com

Contacts

Covicept Therapeutics, Inc.
Professor Tsimikas, Co-Founder, Chairman and Chief Executive Officer
Tel: +1 (0) 858 699 3528
Sander van Deventer, Covicept Board director and Forbion Operating Partner
Tel: +31 (0) 6 5498 2592

Forbion
Laura Asbjornsen, Head of Communications
Email: laura.asbjornsen@forbion.com
Tel: +31 (0) 35 699 30 00

Consilium Strategic Communications
Ashley Tapp, Sue Charles, Kris Lam
Email: Covicept@consilium-comms.com
Tel: +44 (0)20 3709 5700

TORONTO and MINNEAPOLIS, Oct. 05, 2021 (GLOBE NEWSWIRE) — Ceridian (NYSE: CDAY; TSX: CDAY), a global leader in human capital management (HCM) technology, today announced plans to deliver Dayforce Payroll across nine new markets, including Germany, Hong Kong, Indonesia, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand.

Today, organizations around the world use Dayforce Payroll to reduce global compliance complexities and enable real-time auditing of payroll data to pay their people accurately and on time. Dayforce Payroll bridges the gap between pay and time, removing the pressure and burden of the traditional payroll process.

“The Dayforce platform’s continuous calculation of pay and time within a single solution has redefined how global enterprises experience payroll,” said Joe Korngiebel, Chief Product and Technology Officer, Ceridian. “We’re excited to bring Dayforce Payroll to nine new markets to drive increased business value for our customers, while delivering superior user experiences for their people.”

With ever-changing compliance and regulatory requirements, multinational organizations can achieve a competitive advantage by adopting a modern payroll solution that helps minimize risk and protect the bottom line. Ceridian seamlessly facilitates global pay in over 160 countries allowing employers to navigate their international workforces through one consolidated system, including country-specific details down to the employee level.

“We look forward to helping our customers with operations in APJ and EMEA to better navigate the complexities of today’s business world by providing accurate, compliant, and always-on payroll solutions as part of our global HCM leadership,” concluded Korngiebel.

We anticipate that Dayforce Payroll will be available in these new markets beginning in 2022. To learn more about Dayforce Payroll, visit: Ceridian.com/Payroll

About Ceridian
Ceridian. Makes Work Life Better™.
Ceridian is a global human capital management software company. Dayforce, our flagship cloud HCM platform, provides human resources, payroll, benefits, workforce management, and talent management functionality. Our platform is used to optimize management of the entire employee lifecycle, including attracting, engaging, paying, deploying, and developing people. Ceridian has solutions for organizations of all sizes. Visit Ceridian.com or follow us @Ceridian.

Forward-Looking Statement

This press release contains forward-looking statements that involve a number of risks and uncertainties. Statements that are not historical facts, and our expectations, hopes, intentions or strategies regarding the future are forward-looking statements. Forward-looking statements are based on management’s beliefs, as well as assumptions made by, and information currently available to, management. Because such statements are based on expectations as to the future and are not statements of fact, actual results may differ materially from those projected. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

This press release should be read in conjunction with the risks detailed in the “Cautionary Note Regarding Forward-Looking Information,” “Forward-Looking Statement”, “Risk Factors” and other sections of Ceridian’s Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K and other filings with the Securities and Exchange Commission.

Media Contact:

Fahd Pasha
647.417.2136
Fahd.Pasha@Ceridian.com